RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company’s management team will participate in the following investor conferences in November 2023.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company’s management team will participate in the following investor conferences in November 2023:
- Truist Securities BioPharma Symposium: Panel discussion on Wednesday, November 8 at 10:45 a.m. ET in New York.
- Jefferies London Healthcare Conference: Presentation on Wednesday, November 15 at 12:00 p.m. GMT (7:00 a.m. ET) in London, England.
- Evercore ISI HealthCONx Conference: Fireside chat on Thursday, November 30 at 10:00 a.m. ET in Miami.
RayzeBio will also be participating in 1x1 investor meetings at these conferences.
About RayzeBio
RayzeBio is building a vertically integrated radiopharmaceutical therapeutics (RPT) company to treat various cancers, with its lead program in a Phase 3 clinical trial. RayzeBio has created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Much like antibody drug conjugates emerged as a new and transformative treatment modality in certain cancers, the company sees an opportunity for innovative radiopharmaceutical therapeutics to follow a similar path. RayzeBio believes its strategic investments in building a robust product pipeline, development capabilities, and manufacturing infrastructure position the company to be an industry-leading pioneer in the broad application of RPT for cancer.
Contact: Arvind Kush
Email: info@rayzebio.com
